Quantitative Concept – Page 12

AstraZeneca Discontinues Vemircopan, Takes $753M Charge on Former Alexion Asset

3 months ago talkbio0Tagged Alexion, AstraZeneca, charge amounts, Complement Inactivating Agents, drug discontinuation, Drug Industry, Impaired, Vemircopan

AstraZeneca, Alexion, vemircopan, complement inhibitor, drug discontinuation, impairment charge, rare diseases, pharmaceutical industry

LinusBio Introduces ClearStrand-ASD: Revolutionary Autism Diagnostic Aid Using Hair Analysis

3 months ago talkbio0Tagged Autistic Disorder, biomarker test, ClearStrand-ASD, Detection, Diagnosis, Exposome, Hair Analysis, LinusBio, Negative Predictive Value of Diagnostic Test

LinusBio, ClearStrand-ASD, autism diagnostic, hair analysis, biomarker test, early detection, negative predictive value, exposome medicine

Congressional Healthcare Reform Priorities Under Trump’s Second Term

3 months ago talkbio0Tagged Alcohol abuse, Medicaid block grants, Medicare, Prices, repeal, Translucent, Value-Based Care

ACA repeal, Medicaid block grants, price transparency, Medicare Advantage, drug pricing, value-based care

EyePoint Pharmaceuticals Reports Positive Phase 2 Results for DURAVYU in Wet AMD, Challenging Established Anti-VEGF Therapies

3 months ago talkbio0Tagged AMD, anti-VEGF therapy, Clinical Trials, DURAVYU, EyePoint Pharmaceuticals, Glycogen storage disease type II, Movement, Prices, vorolanib

DURAVYU, vorolanib, wet AMD, anti-VEGF therapy, EyePoint Pharmaceuticals, clinical trial results, stock price movement

Pharmaceutical Industry Warns of Drug Shortages and Price Hikes Due to Trump’s New Tariffs

3 months ago talkbio0Tagged Active, APIs, chain disruption, Drug Industry, Drug shortages, Groups, Increased, Prices, TNFRSF19 gene, Trump tariffs

Trump tariffs, drug shortages, price increases, pharmaceutical industry, trade groups, supply chain disruption, generic drugs, active pharmaceutical ingredients (APIs)

Pfizer Exceeds Q4 Expectations: COVID-19 Products and Cost-Cutting Drive Strong Performance

3 months ago talkbio0Tagged Advice, cost-cutting initiatives, COVID19 (disease), earnings, financial recovery, Pfizer, portfolio, revenue growth

Pfizer, Q4 earnings, COVID-19 portfolio, cost-cutting initiatives, revenue growth, Paxlovid, financial recovery, 2025 guidance

Turnstone Biologics Discontinues Final Clinical Program, Initiates Strategic Review Amid Financial Constraints

3 months ago talkbio0Tagged Arenaria, Biological Factors, clinical program, Discontinuation (procedure), Financial cost, Industry, Lymphocytes, Tumor-Infiltrating, Manufacturing, strategic alternatives, TIDAL-01

Turnstone Biologics, TIDAL-01, clinical program discontinuation, layoffs, strategic alternatives, TIL therapy, manufacturing costs, biotech industry challenges